The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,360.00
Bid: 12,328.00
Ask: 12,332.00
Change: -4.00 (-0.03%)
Spread: 4.00 (0.032%)
Open: 12,358.00
High: 12,376.00
Low: 12,256.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on the Phase III EAGLE trial of Imfinzi

7 Dec 2018 07:00

RNS Number : 7484J
AstraZeneca PLC
07 December 2018
 

7 December 2018 07:00 GMT

 

Update on the Phase III EAGLE trial of Imfinzi andtremelimumab in advanced head and neck cancer

 

AstraZeneca and MedImmune, its global biologics research and development arm, today announced overall survival (OS) results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trial evaluating Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression following platinum-based chemotherapy, regardless of their PD-L1 tumour status.

 

Imfinzi monotherapy and the combination of Imfinzi plus tremelimumab did not meet the primary endpoints of improving OS compared to SoC chemotherapy in these hard-to-treat patients. The safety and tolerability profiles for Imfinzi and the combination with tremelimumab were consistent with previous experience.

 

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, said: "The prognosis for recurrent or metastatic head and neck squamous cell cancer is very poor and new treatments for this group of cancers are urgently needed. While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer. We look forward to seeing the results of the Phase III KESTREL trial of Imfinzi and tremelimumab in patients who have not received prior chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma in the first half of 2019."

 

AstraZeneca will submit the results from the Phase III EAGLE trial for presentation at a forthcoming medical meeting.

 

About EAGLE

The EAGLE trial is a randomised, open-label, multi-centre, global, Phase III trial of Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab compared to standard-of-care chemotherapy in patients with recurrent or metastatic HNSCC who experienced progression following platinum-based chemotherapy, regardless of their PD-L1 tumour status.

 

The trial was conducted at 169 centres across 24 countries including the US, Europe, South America, Japan, Korea, Taiwan, Israel and Australia. The primary endpoint of the trial was OS, and secondary endpoints included progression-free survival, landmark OS, objective response rate and duration of response.

 

About HNSCC

Approximately 880,000 patients were diagnosed with head and neck cancer around the world in 2018. Two-thirds of patients diagnosed with head and neck cancer are in advanced stages (Stage III or IV), while the remaining one third are in the early stages of disease (Stage I or II). More than 90% of all head and neck cancers start in the squamous cells that line the mouth, nose and throat called head and neck squamous cell carcinomas (HNSCC).

 

About Imfinzi

Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.

 

Imfinzi is approved for unresectable, Stage III non-small cell lung cancer (NSCLC) in more than 40 countries including the US, EU, and Japan based on the Phase III PACIFIC trial. Imfinzi is also approved for previously-treated patients with advanced bladder cancer in the US, Canada, Brazil, Israel, India, United Arab Emirates, Australia and Hong Kong.

 

As part of a broad development programme, Imfinzi is also being tested as a monotherapy and in combination with tremelimumab, an anti-CTLA4 monoclonal antibody and potential new medicine, as a treatment for patients with NSCLC, small-cell lung cancer (SCLC), bladder cancer, head and neck cancer and other solid tumours.

 

About tremelimumab

Tremelimumab is a human monoclonal antibody and potential new medicine that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Tremelimumab blocks the activity of CTLA-4, contributing to T-cell activation and boosting the immune response to cancer. Tremelimumab is being tested in a clinical trial programme in combination with Imfinzi in NSCLC, SCLC, bladder cancer, head and neck squamous cell carcinoma, liver cancer and blood cancers.

 

About AstraZeneca's approach to immuno-oncology

IO is a therapeutic approach designed to stimulate the body's immune system to attack tumours. At AstraZeneca and MedImmune, our biologics research and development arm, our IO portfolio is anchored by immunotherapies that have been designed to overcome anti-tumour immune suppression. We believe that IO-based therapies offer the potential for life-changing cancer treatments for the clear majority of patients.

 

We are pursuing a comprehensive clinical-trial programme that includes Imfinzi (anti-PDL1) as monotherapy and in combination with tremelimumab (anti-CTLA4) in multiple tumour types, stages of disease, and lines of therapy, using the PD-L1 biomarker as a decision-making tool to define the best potential treatment path for a patient. In addition, the ability to combine our IO portfolio with small, targeted molecules from across our Oncology pipeline, and from our research partners, may provide new treatment options across a broad range of tumours.

 

About AstraZeneca in oncology

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients' lives and the Company's future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance Oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.

 

By harnessing the power of four scientific platforms - Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates - and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

 

 

About MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of small-molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology; Respiratory; Cardiovascular, Renal & Metabolic Diseases; and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, MD, one of AstraZeneca's three global R&D centres, with additional sites in Cambridge, UK, and South San Francisco, CA. For more information, please visit www.medimmune.com.

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations

 

 

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Gonzalo Viña

UK/Global

+44 203 749 5916

Jennifer Hursit

UK/Global

+44 203 749 5762

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

 

Investor Relations

Thomas Kudsk Larsen

 

+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

Cardiovascular; Metabolism

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

Josie Afolabi

Other

+44 203 749 5631

Craig Marks

Finance; Fixed Income

+44 7881 615 764

Jennifer Kretzmann

Retail Investors

+44 203 749 5824

US toll-free

 

+1 866 381 7277

     

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RESUNOARWWAURUA
Date   Source Headline
1st Sep 20203:00 pmRNSTotal Voting Rights
1st Sep 20207:00 amRNSImfinzi approved in EU for small cell lung cancer
1st Sep 20207:00 amRNSFarxiga reduces CKD progression and risk of death
25th Aug 20207:00 amRNSPh I trial begins for COVID-19 monoclonal antibody
21st Aug 20207:00 amRNSImfinzi approved in Japan for SCLC
18th Aug 20207:00 amRNSImfinzi US Priority Review; four-week, fixed dose
4th Aug 20207:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20203:00 pmRNSTotal Voting Rights
30th Jul 20207:25 amRNSTagrisso US BTD for EGFRm adjuvant lung cancer
30th Jul 20207:18 amRNSAZN: H1 2020 results
29th Jul 20207:00 amRNSBoard Committee Changes
28th Jul 20207:00 amRNSFarxiga DAPA-CKD trial met all endpoints
27th Jul 20207:10 amRNSCalquence receives positive CHMP opinion for CLL
27th Jul 20207:05 amRNSImfinzi recommended for EU approval in SCLC
27th Jul 20207:00 amRNSAstraZeneca enters collaboration in oncology
24th Jul 20207:00 amRNSBreztri Aerosphere approved in the US for COPD
22nd Jul 20203:00 pmRNSHolding(s) in Company
22nd Jul 20203:00 pmRNSHolding(s) in Company
21st Jul 20203:00 pmRNSHolding(s) in Company
21st Jul 20203:00 pmRNSHolding(s) in Company
20th Jul 20202:41 pmRNSCOVID-19 vaccine Phase I/II showed immune response
16th Jul 20207:00 amRNSDirector Declaration
9th Jul 20207:00 amRNSBrilinta granted US FDA Priority Review for stroke
8th Jul 20207:00 amRNSLynparza approved in the EU for pancreatic cancer
1st Jul 20203:00 pmRNSTotal Voting Rights
30th Jun 20203:00 pmRNSDirector/PDMR Shareholding
30th Jun 20207:00 amRNSSelumetinib granted Japan orphan drug designation
17th Jun 20203:03 pmRNSHolding(s) in Company
17th Jun 20203:00 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSAgreement to Supply Europe with COVID-19 Vaccine
11th Jun 20207:00 amRNSEMTN Programme Routine Technical Update
1st Jun 20203:00 pmRNSBlock listing Interim Review
1st Jun 20203:00 pmRNSTotal Voting Rights
1st Jun 20207:00 amRNSLynparza EU CHMP opinion in pancreatic cancer
1st Jun 20207:00 amRNSBrilinta obtains additional US approval
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:35 pmRNSPrice Monitoring Extension
29th May 20201:00 pmRNSImfinzi sustained overall survival in CASPIAN
29th May 20201:00 pmRNSEnhertu DESTINY-Gastric01 results from ASCO 2020
29th May 20207:00 amRNSTagrisso unprecedented adjuvant lung cancer data
26th May 202010:30 amRNSDirector/PDMR Shareholding
22nd May 20207:00 amRNSEnhertu US orphan designation in gastric cancer
21st May 20207:00 amRNSAstraZeneca advances response to COVID-19 outbreak
20th May 20207:00 amRNSLynparza approved in the US for prostate cancer
18th May 20207:00 amRNSEnhertu US Breakthrough status for lung cancer
18th May 20207:00 amRNSBevespi Aerosphere approved in China for COPD
11th May 20207:00 amRNSEnhertu designated gastric cancer BTD
11th May 20207:00 amRNSLynparza gets broader US ovarian cancer approval
11th May 20207:00 amRNSBrazikumab rights recovered by AstraZeneca
6th May 20207:00 amRNSFarxiga approved by FDA for heart failure (HFrEF)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.